| Chen, Xiaoping |
NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. |
|
|
| Recruiting | 4 | 300 | RoW | HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06311929: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 300 | RoW | PD-1 monoclonal antibody and lenvatinib, Non, PD-1 monoclonal antibody | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06311916: Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. |
|
|
| Not yet recruiting | 4 | 312 | NA | HAIC + Tirelizumab +lenvatinib +liver resection, Non, liver resection | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
SPH3127-301, NCT05359068: Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension |
|
|
| Completed | 3 | 957 | RoW | SPH3127 tablet, Valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Essential Hypertension | 12/23 | 12/23 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
| Recruiting | 2 | 62 | RoW | ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w | Abbisko Therapeutics Co, Ltd | Hepatocellular Carcinoma | 07/24 | 10/24 | | |
NCT04076631: Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 1000 | RoW | | Chen Xiaoping | Hepatocellular Carcinoma, Liver Cirrhosis | 11/20 | 12/20 | | |
NCT03652896: Anatomy-based Resection or Margin-based Resection for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 60 | RoW | anatomical liver resection, non-anatomical liver resection | Huazhong University of Science and Technology | Hepatocellular Carcinoma by BCLC Stage | 12/21 | 12/23 | | |
| Not yet recruiting | N/A | 5000 | RoW | Endovascular Therapy | Chinese Academy of Medical Sciences, Fuwai Hospital | Renal Artery Obstruction, Hypertension, Renovascular | 04/22 | 04/24 | | |
ASORPWICE, NCT03521739: Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events |
|
|
| Recruiting | N/A | 100000 | RoW | | Chinese Academy of Medical Sciences, Fuwai Hospital | Blood Pressure, Pulse Wave Analysis, Ankle Brachial Index, Patient Outcome Assessment | 12/22 | 12/23 | | |
NCT00258570: Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | N/A | 2000 | US | | University of Pittsburgh | Pulmonary Fibrosis | 07/35 | 07/35 | | |
NCT00258583: Dorothy P. and Richard P. Simmons Center for ILD Research Registry |
|
|
| Recruiting | N/A | 5000 | US | | University of Pittsburgh | Lung Diseases, Interstitial | 07/35 | 07/35 | | |
NCT00373841: Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF) |
|
|
| Recruiting | N/A | 500 | US | | University of Pittsburgh | Idiopathic Pulmonary Fibrosis | 07/30 | 07/30 | | |
NCT05420922: Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC |
|
|
| Recruiting | N/A | 2000 | RoW | Lenvatinib Oral Product, PD-1 inhibitor, Local treatment | Tongji Hospital | Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy | 08/22 | 12/22 | | |
| zhu, peng |
NCT06248554: Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation |
|
|
| Recruiting | N/A | 200 | RoW | PD-1 Inhibitors | Chen Xiaoping | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
CHALLENGE-01, NCT06248528: Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. |
|
|
| Recruiting | N/A | 200 | RoW | Liver resection, Locoregional therapy | Chen Xiaoping | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
| Zhang, Wanguang |
NCT06311929: Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma |
|
|
| Recruiting | 4 | 300 | RoW | PD-1 monoclonal antibody and lenvatinib, Non, PD-1 monoclonal antibody | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
NCT06311942: Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. |
|
|
| Recruiting | 4 | 300 | RoW | HAIC plus PD-1 inhibitors plus lenvatinib, Non, PD-1 inhibitors plus lenvatinib | Chen Xiaoping | HCC | 12/27 | 12/28 | | |
CCGLC-005, NCT05236699: A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC |
|
|
| Recruiting | 2 | 18 | RoW | DEB-TACE combined with Surufatinib and Camrelizumab | Tongji Hospital | Intrahepatic Cholangiocarcinoma | 06/24 | 01/25 | | |
CCGLC-010, NCT05839197: A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC |
|
|
| Recruiting | 2 | 38 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Camrelizumab plus Apatinib | Wan-Guang Zhang | Macrotrabecular Massive Hepatocellular Carcinoma | 04/25 | 04/25 | | |
NCT06463444: Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models |
|
|
| Recruiting | 1 | 30 | RoW | HAIC + Tislelizumab +lenvatinib | Chen Xiaoping | HCC, Precision Therapy | 06/25 | 06/26 | | |
NCT06248554: Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation |
|
|
| Recruiting | N/A | 200 | RoW | PD-1 Inhibitors | Chen Xiaoping | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
CHALLENGE-01, NCT06248528: Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. |
|
|
| Recruiting | N/A | 200 | RoW | Liver resection, Locoregional therapy | Chen Xiaoping | Hepatocellular Carcinoma | 10/24 | 12/24 | | |
NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer |
|
|
| Withdrawn | N/A | 300 | RoW | Observation | Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital | Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma | 03/23 | 03/23 | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
CCGLC-006, NCT05520788: Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing |
|
|
| Recruiting | N/A | 200 | RoW | precise medicine | Tongji Hospital | Hepatocellular Carcinoma, Biliary Tract Cancer | 12/25 | 12/25 | | |
